Clinical Trial Detail

NCT ID NCT01233687
Title AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ahmad Tarhini
Indications

lung non-small cell carcinoma

Therapies

Rilotumumab

Erlotinib

Age Groups: adult senior

No variant requirements are available.